Not later than 6 months after July 9, 2012, and annually thereafter, the Attorney General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on the Judiciary of the Senate a report on drug shortages that—
(1)identifies the number of requests received under section
826(h) of this title (as added by section 1005 of this Act), the average review time for such requests, the number of requests granted and denied under such section, and, for each of the requests denied under such section, the basis for such denial;
(2)describes the coordination between the Drug Enforcement Administration and Food and Drug Administration on efforts to prevent or alleviate drug shortages; and
(3)identifies drugs containing a controlled substance subject to section
826 of this title when such a drug is determined by the Secretary to be in shortage.
Section 1005 of this Act, referred to in par. (1), means section 1005 ofPub. L. 112–144, which amended section
826 of this title.
Section was enacted as part of the Food and Drug Administration Safety and Innovation Act, and not as part of the Controlled Substances Act which comprises this subchapter.
Definition of “Secretary”
The term “Secretary” as meaning the Secretary of Health and Human Services, see section 1001(b) ofPub. L. 112–144, set out as an Effect of Notification note under section
356c of this title.
The table below lists the classification updates, since Jan. 3, 2012, for this section. Updates to a broader range of sections may be found at the update page for containing chapter, title, etc.
The most recent Classification Table update that we have noticed was Tuesday, August 13, 2013
An empty table indicates that we see no relevant changes listed in the classification tables. If you suspect that our system may be missing something, please double-check with the Office of the Law Revision Counsel.